Approved & Available
FDA approved (2014), EMA approved, WHO recommended. Used in 130+ countries.
Gardasil 9
Also known as: HPV9 · V503 · Human Papillomavirus 9-valent Vaccine
Gardasil 9 is the gold-standard HPV vaccine, protecting against 9 strains of human papillomavirus responsible for ~90% of HPV-related cancers. HPV causes virtually all cervical cancers, the majority of oropharyngeal cancers, and significant proportions of anal, vulvar, vaginal, and penile cancers. A 2-dose or 3-dose schedule (depending on age) provides long-lasting immunity. Mass vaccination programs have already driven dramatic reductions in cervical cancer rates in countries with high uptake — Scotland reported near-elimination of cervical cancer in the first vaccinated generation.
What It Targets
Target Antigen
HPV strains 6, 11, 16, 18, 31, 33, 45, 52, 58 (L1 protein VLPs)
Cancers Targeted
How It Works
Virus-Like Particles (VLPs) made from the HPV L1 outer shell protein (no live virus, no DNA) trigger strong antibody production. When the real virus is encountered, neutralising antibodies block it from infecting cervical and mucosal cells, preventing the persistent infection that leads to dysplasia and eventually cancer over 10–20 years.
Key Trial Results
- 99.8% efficacy against CIN2/3 (precancerous lesions from HPV 16/18) in clinical trials
- Scotland: near-elimination of cervical cancer in women vaccinated before age 14 — first real-world evidence of population-level cancer elimination
- Australia achieved <4 cases per 100,000 (elimination threshold) by 2022 after school-based program
- Reduces oropharyngeal HPV infection by 88% — expected to slash throat cancer rates by 2040s
- Herd immunity effects: unvaccinated individuals in high-uptake countries also show reduced HPV prevalence
- Long-term follow-up shows durable antibody titres for 10+ years with no booster needed
Regulatory Status & Availability
Approval Status
FDA approved (2014), EMA approved, WHO recommended. Used in 130+ countries.
Estimated Availability
Available now — recommended ages 9–45 (US), 9–26 primary schedule
Important Considerations
- Not a treatment — must be given before HPV exposure for maximum benefit; still beneficial after partial exposure
- Does not replace cervical screening (Pap smear / HPV test) — vaccinated women should still be screened
- Common side effects: injection site pain, redness, swelling; rare: fainting post-injection
- Not recommended during pregnancy (defer until post-partum)
- Discuss with oncologist before vaccinating during active cancer treatment
Research References
iOnco provides this information for educational purposes only. Cancer vaccine availability, trial eligibility, and access pathways change frequently. Always discuss vaccination decisions and clinical trial participation with your oncologist or healthcare provider.